MX2024003215A - Metodo de tratamiento del mieloma multiple. - Google Patents
Metodo de tratamiento del mieloma multiple.Info
- Publication number
- MX2024003215A MX2024003215A MX2024003215A MX2024003215A MX2024003215A MX 2024003215 A MX2024003215 A MX 2024003215A MX 2024003215 A MX2024003215 A MX 2024003215A MX 2024003215 A MX2024003215 A MX 2024003215A MX 2024003215 A MX2024003215 A MX 2024003215A
- Authority
- MX
- Mexico
- Prior art keywords
- multiple myeloma
- treatment method
- methods
- myeloma treatment
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/06—Ampoules or carpules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163244113P | 2021-09-14 | 2021-09-14 | |
| US202163285435P | 2021-12-02 | 2021-12-02 | |
| US202263400882P | 2022-08-25 | 2022-08-25 | |
| PCT/US2022/042944 WO2023043658A2 (en) | 2021-09-14 | 2022-09-08 | Method of treating multiple myeloma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024003215A true MX2024003215A (es) | 2024-07-19 |
Family
ID=85603424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003215A MX2024003215A (es) | 2021-09-14 | 2022-09-08 | Metodo de tratamiento del mieloma multiple. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240392028A1 (https=) |
| EP (1) | EP4401839A4 (https=) |
| JP (1) | JP2024535132A (https=) |
| KR (1) | KR20240055101A (https=) |
| AU (1) | AU2022346750A1 (https=) |
| CA (1) | CA3231073A1 (https=) |
| MX (1) | MX2024003215A (https=) |
| WO (1) | WO2023043658A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025194030A1 (en) * | 2024-03-15 | 2025-09-18 | Alexion Pharmaceuticals, Inc. | Treatment of mayo stage iiib light chain amyloidosis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5553963B2 (ja) * | 2004-10-22 | 2014-07-23 | アムジエン・インコーポレーテツド | 組換え抗体をリフォールディングする方法 |
| CR20190291A (es) * | 2016-12-23 | 2019-11-05 | Serum Institute Of India Pvt Ltd | Métodos mejorados para estimular la productividad de anticuerpos en el cultivo de células de mamiferos y reducir la agregación durante los procesos de formulación post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos |
| US20190298827A1 (en) * | 2018-04-03 | 2019-10-03 | Janssen Biotech, Inc. | Methods of Treating Multiple Myeloma |
| EP4058479A4 (en) * | 2019-11-15 | 2024-02-28 | University of Tennessee Research Foundation | MODIFIED IMMUNOLOBULINES FOR TARGETING AMYLOID DEPOSITS |
| AU2021339851A1 (en) * | 2020-09-14 | 2023-04-13 | Caelum Biosciences, Inc. | Method of treating amyloidosis |
-
2022
- 2022-09-08 AU AU2022346750A patent/AU2022346750A1/en active Pending
- 2022-09-08 CA CA3231073A patent/CA3231073A1/en active Pending
- 2022-09-08 KR KR1020247011913A patent/KR20240055101A/ko active Pending
- 2022-09-08 EP EP22870530.7A patent/EP4401839A4/en active Pending
- 2022-09-08 MX MX2024003215A patent/MX2024003215A/es unknown
- 2022-09-08 US US18/691,365 patent/US20240392028A1/en active Pending
- 2022-09-08 WO PCT/US2022/042944 patent/WO2023043658A2/en not_active Ceased
- 2022-09-08 JP JP2024540838A patent/JP2024535132A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4401839A2 (en) | 2024-07-24 |
| WO2023043658A3 (en) | 2023-05-11 |
| CA3231073A1 (en) | 2023-03-23 |
| KR20240055101A (ko) | 2024-04-26 |
| US20240392028A1 (en) | 2024-11-28 |
| AU2022346750A1 (en) | 2024-04-11 |
| JP2024535132A (ja) | 2024-09-26 |
| EP4401839A4 (en) | 2025-08-06 |
| WO2023043658A2 (en) | 2023-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2025000404A1 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
| CL2022001189A1 (es) | Anticuerpos para cd40. (divisional de solicitud n° 2017003427) | |
| MX2023000735A (es) | Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer. | |
| CL2018002708A1 (es) | Métodos para la inhibición de la angiogénesis en un sujeto que lo necesita | |
| CL2020003256A1 (es) | Métodos para el tratamiento del cáncer con anticuerpos anti-cd3xmuc16 y anticuerpos anti-pd-1 biespecíficos. | |
| MX2020009862A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| CL2019000585A1 (es) | Combinación de un anticuerpo anti-cd20, inhibidor pi3 kinase-delta y anticuerdo anti-pd-1 o anti-pd-l1 para el tratamiento de cánceres hematológicos. | |
| CR20190162A (es) | Métodos para usar un anticuerpo biespecífico que reconoce el factor de coagulación ix y/o el factor de coagulación ix activado y el factor de coagulación x y/o el factor de coagulación x activado | |
| CL2020002075A1 (es) | Métodos para tratar el cáncer con anticuerpos anti-pd1. | |
| CO2025011012A2 (es) | Agonistas heterocíclicos de glp-1 | |
| MX2022011258A (es) | Una terapia combinada con nirogacestat y una terapia dirigida a bcma y usos de estas. | |
| CL2023000741A1 (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos. | |
| MX2021009079A (es) | Metodos para tratar el mieloma multiple. | |
| MX2021013296A (es) | Politerapia para tratar enfermedades artriticas. | |
| MX2022001133A (es) | Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido). | |
| CO2018001599A2 (es) | Un inhibidor de anticuerpo monoclonal de factor xiia | |
| AR107983A1 (es) | Métodos para tratar eventos adversos gastrointestinales relacionados con el sistema inmunitario en tratamientos de combinación anti-ctla4 anti-pd-1 | |
| CL2019003485A1 (es) | Métodos para redicur la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a. (divisional solicitud 201900909) | |
| MX2023014500A (es) | Medicamento para el tratamiento y/o prevencion de cancer. | |
| MX2018000135A (es) | Terapia combinada con un conjugado de farmaco y anticuerpo anti receptor 2 de factor de crecimiento epidermico humano (her2) y un inhibidor de linfoma de celulas b2 (bcl-2). | |
| MX2024003215A (es) | Metodo de tratamiento del mieloma multiple. | |
| CL2021000585A1 (es) | Métodos para tratar la pancreatitis | |
| MX2025012459A (es) | Métodos para tratar el mieloma múltiple | |
| MX2021006915A (es) | Inhibidores de cxcr7 para el tratamiento de cancer. | |
| MX2022011845A (es) | Terapia combinada con un inhibidor de idh mutante y un inhibidor de bcl-2. |